J. Beck

发表

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.

P. Fasching, P. Neven, S. Im, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

H. Rugo, H. Wildiers, L. Paz-Ares, 2022, npj Breast Cancer.

LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

P. Fasching, P. Neven, C. Wang, 2022, Annals of Oncology.

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

Anand A. Dalal, G. Hortobagyi, B. Ramaswamy, 2019, Clinical breast cancer.

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

G. Hortobagyi, D. Cameron, L. Hart, 2017, Breast Cancer Research and Treatment.

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

P. Wen, T. Cloughesy, N. Butowski, 2019, Neuro-oncology.

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

P. Neven, F. Esteva, X. Pivot, 2019, Annals of Oncology.

Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

H. Rugo, H. Wildiers, P. Kabos, 2020 .

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

N. Pathan, W. Messersmith, S. Rottey, 2023, ESMO open.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

P. Neven, C. Wang, G. Jerusalem, 2023, Breast Cancer Research.